Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target Raised to $14.00 at Oppenheimer

Corvus Pharmaceuticals (NASDAQ:CRVS) had its price target lifted by Oppenheimer from $8.00 to $14.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other equities analysts have also recently weighed in on CRVS. StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. Finally, LADENBURG THALM/SH SH raised their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Corvus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $12.83.

Corvus Pharmaceuticals Stock Down 3.9 %

Shares of NASDAQ CRVS opened at $8.19 on Wednesday. The stock’s fifty day simple moving average is $6.75 and its 200 day simple moving average is $4.00. The stock has a market capitalization of $512.28 million, a price-to-earnings ratio of -8.81 and a beta of 1.05. Corvus Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $10.00.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new stake in shares of Corvus Pharmaceuticals in the second quarter worth approximately $44,000. Nwam LLC acquired a new position in Corvus Pharmaceuticals in the 3rd quarter valued at approximately $53,000. XTX Topco Ltd purchased a new stake in Corvus Pharmaceuticals in the 3rd quarter worth approximately $74,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter valued at $89,000. Finally, Marshall Wace LLP acquired a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter valued at $136,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.